Clinical Trial Update: A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease [Phase 2]

View source ↗

Summary

Phase 2 trial of panobinostat (LBH589) as second-line therapy for chronic graft-versus-host disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Panobinostat (Panobinostat)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Chronic Graft-Versus-Host Disease | Phase 2 | Status: WITHDRAWN